In a strategic move aimed at advancing cardiac arrhythmia treatment, Johnson & Johnson MedTech recently announced the acquisition of Laminar, Inc., a privately-held medical device company specializing in eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). The acquisition, involving an upfront payment of $400 million, underscores Johnson & Johnson's commitment to expanding its capabilities in the field of cardiovascular health.
Laminar's expertise in addressing the risk of thromboembolism in AFib patients aligns seamlessly with Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and a key subsidiary of Johnson & Johnson MedTech. AFib, a condition affecting approximately 38 million patients worldwide, increases the likelihood of stroke fivefold. The left atrial appendage, a small pouch in the heart, is a potential source of clots that can lead to stroke, particularly in patients with non-valvular atrial fibrillation.
The company's innovative approach involves the use of rotational motion to eliminate the LAA, distinguishing it from other catheter-based procedures that use plugs to occlude the appendage. The FDA has approved its therapy as a means to reduce the risk of thromboembolism in AFib patients who are recommended for chronic oral anticoagulation therapy, particularly beneficial for the nearly 40% of patients unable to tolerate long-term blood thinners.
Randy Lashinski, President & CEO of Laminar, emphasized, "For the millions of people living with AFib, stroke risk is a major concern. The team at Laminar is driven by our vision to develop and deliver an innovative solution to help patients live without the fear of stroke, or the need for long-term use of blood thinners." Jasmina Brooks, President of Biosense Webster, expressed excitement about the collaboration, stating, "Laminar’s innovative approach will provide Biosense Webster the opportunity to expand our portfolio in this high growth market, complement our electrophysiology and Intracardiac Echo strengths, and deepen our presence with interventional cardiologists and electrophysiologists. Fueled by the global scale and commercial and clinical strength of Biosense Webster, we are excited to explore the possibilities ahead to reach even more patients with critical unmet need."
As a result of the acquisition, Johnson & Johnson MedTech anticipates an in-process research and development charge, impacting operational and reported Adjusted EPS. Despite this, the company remains steadfast in its commitment to diversifying healthcare expertise and utilizing purposeful technology to transform medical interventions, ultimately empowering individuals to live their best lives.
Headquartered in Irvine, California, Biosense Webster continues to lead the global industry in the science and technology behind the diagnosis and treatment of cardiac arrhythmias. The company's work spans the globe, advancing tools and solutions that enable electrophysiologists to identify, treat, and deliver comprehensive care.
In summary, this acquisition underscores the company’s dedication to advancing healthcare solutions, particularly in the critical field of cardiac arrhythmia treatment. The collaboration with Biosense Webster positions the conglomerate at the forefront of innovations that aim to address the complex challenges faced by AFib patients and reduce the global burden of stroke associated with this prevalent condition.
